Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome

Neurology

Volumn 46, Issue 1, 1996, Pages 100-103

  Bril, V ^a,d   Ilse, W K ^b   Pearce, R ^c   Dhanani, A ^a   Sutton, D ^a   Kong, K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WINNIPEG   (Canada)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PLASMA EXCHANGE; POLYRADICULONEUROPATHY; PROGNOSIS;

EID: 0030006629     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.1.100     Document Type: Article

References (26)

1. Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet 1978;2:1100.
2. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22:753-761.
3. GBS Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-1104.
4. Greenwood RJ, Hughes RAC, Bowden AN, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;1:877-879.
5. Mendell JR, Kissel JT, Kennedy MS, et al. Plasma exchange and prednisone in Guillain-Barré syndrome: a controlled randomized trial. Neurology 1985;35:1551-1555.
6. NIH Consensus Development. The utility of therapeutic plasmapheresis for neurological disorders. JAMA 1986;256:1333-1337.
7. McKhann GM. Guillain-Barré syndrome: clinical and therapeutic observations. Ann Neurol 1990;27(suppl):S13-S16.
8. Osterman PO, Fagius J, Safwenberg J, Danielsson BG, Wikstrom B. Early relapses after plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1986;2:1161.
9. Osterman PO, Lundemo G, Pirskanen R, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;2:1296-1298.
10. Kleyweg RP, van der Meché FGA. Treatment-related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma exchange. J Neurol Neurosurg Psychiatry 1991;54:957-960.
11. Ropper AH, Albers JW, Addison R. Limited relapse in Guillain-Barré syndrome after plasma exchange. Arch Neurol 1988;45:314-315.
12. Boucher CA, de Gans J, van Oers R, Danner S, Goudsmit J. Transmission of HIV and AIDS by plasmapheresis for Guillain-Barré syndrome. Clin Neurol Neurosurg 1988;90:235-236.
13. Hughes RAC, Newson-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2:750-753.
14. Hughes RAC, Kadlubowski M, Hufschmidt A. Treatment of acute inflammatory polyneuropathy. Ann Neurol 1981; 9(suppl):125-133.
15. Hughes RAC. Ineffectiveness of high-dose intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1991;338: 1142.
16. Vermeulen M, Van Doom PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56:36-39.
17. Vedanarayanan VV, Kandt RS, Lewis DV Jr, DeLong GR. Chronic inflammatory demyelinating polyradiculoneuropathy of childhood: treatment with high-dose intravenous immunoglobulin. Neurology 1991;41:828-830.
18. Faed JM, Day B, Pollock M, Taylor PK, Nukada H, Hammond-Tooke GD. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989;39:422-425.
19. Kleyweg RP, van der Meché FGA, Meultree J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 1988;38:1639-1641.
20. Jackson MC, Godwin-Austen RB, Whiteley AM. High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study. J Neurol 1993;240:51-53.
21. Fasanaro AM, Pizza V, Stella L. Plasma exchange and i.v.-immunoglobulins: new approaches to the treatment of Guillain-Barré syndrome. Acta Neurol(Napoli) 1992;14:369-380.
22. Schuchardt V, Hotz M, Hund E, Sun S, Heitmann R, Hacke W. Experiences with high dosage immunoglobulin G in neuromuscular diseases. Nervenarzt 1993;64:98-103.
23. Van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New Engl J Med 1992;326:1123-1129.
24. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27(suppl):S21-S24.
25. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993;43:1034-1036.
26. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993;43:872-875.